- Home
- SOWG vs MTVA Comparison
SOWG vs MTVA Comparison
Compare SOWG & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- MTVA
- Stock Information
- Founded
- SOWG 2010
- MTVA 2014
- Country
- SOWG United States
- MTVA United States
- Employees
- SOWG N/A
- MTVA N/A
- Industry
- SOWG Packaged Foods
- MTVA
- Sector
- SOWG Consumer Staples
- MTVA
- Exchange
- SOWG Nasdaq
- MTVA NYSE
- Market Cap
- SOWG 23.1M
- MTVA 18.9M
- IPO Year
- SOWG N/A
- MTVA N/A
- Fundamental
- Price
- SOWG $2.35
- MTVA $1.81
- Analyst Decision
- SOWG Strong Buy
- MTVA
- Analyst Count
- SOWG 2
- MTVA 0
- Target Price
- SOWG $23.00
- MTVA N/A
- AVG Volume (30 Days)
- SOWG 143.2K
- MTVA 286.0K
- Earning Date
- SOWG 02-20-2025
- MTVA 11-07-2024
- Dividend Yield
- SOWG N/A
- MTVA N/A
- EPS Growth
- SOWG N/A
- MTVA N/A
- EPS
- SOWG 0.21
- MTVA N/A
- Revenue
- SOWG $40,130,971.00
- MTVA N/A
- Revenue This Year
- SOWG $122.17
- MTVA N/A
- Revenue Next Year
- SOWG N/A
- MTVA N/A
- P/E Ratio
- SOWG $11.20
- MTVA N/A
- Revenue Growth
- SOWG 508.45
- MTVA N/A
- 52 Week Low
- SOWG $2.10
- MTVA $1.51
- 52 Week High
- SOWG $24.83
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- SOWG 19.54
- MTVA N/A
- Support Level
- SOWG $2.10
- MTVA N/A
- Resistance Level
- SOWG $2.51
- MTVA N/A
- Average True Range (ATR)
- SOWG 0.20
- MTVA 0.00
- MACD
- SOWG 0.19
- MTVA 0.00
- Stochastic Oscillator
- SOWG 25.25
- MTVA 0.00
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free granola products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.